Keyword: GW Pharmaceuticals
The panelists said the med's effects on the liver could be managed through labeling and education.
GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.
Therapix Biosciences' THX-110 reduced Tourette symptoms in adults who had failed other treatments.
While the trial linked GWP42006 to around a 40% drop in focal seizures, the placebo triggered a similarly sharp decline.
The failure of the study to hit a single goal or show a dose response raises big doubts about the prospects of the drug.
The early look at the pharmacokinetics achieved by delivering CBD and THC via Intec’s Accordion Pill encouraged the biotech to talk up further trials.
GW Pharma's cannabis-based epilepsy treatment Epidiolex is firmly on track for a filing in the U.S. after new data published in the New England Journal of Medicine showed impressive effects on seizure rates.
Bristol-Myers tapped Thomas Lynch as new CSO, Karaboutis joined a long list of execs who had left Biogen, and Editas bid farewell to its very first employee and COO Glucksmann.
After failing in an ulcerative colitis test a few years back, GW Pharma’s cannabis-derived orphan drug treatment has had better luck in a small oncology study for an aggressive type of brain tumor.
GW Pharma has clocked a third set of positive pivotal trial data, which makes it an even more attractive potential purchase.